David Wilfret, M.D.
Vice President of Clinical Operations
Dr. Wilfret has served as our Vice President of Clinical Operations since February 2021. Dr. Wilfret has over 20 years of experience as a pediatric infectious disease physician and researcher in large pharmaceutical and small biotechnology companies. Prior to joining ContraFect, Dr. Wilfret served as Senior Medical Director at Atox Bio, a biotech developing Reltecimod, an immunomodulator for Necrotizing Soft Tissue Infections and Sepsis-Associated Acute Kidney Injury. There he worked directly on the NDA submission and the Phase 3 studies for these indications. Prior to that, Dr. Wilfret co-founded a small biotechnology company, Symmune Therapeutics which was developing an immunomodulator for prevention and treatment of respiratory tract infections. During this time, he also served as an independent consultant for various pharmaceutical and biotechnology companies, including Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Visterra, and, Alios Biopharma. Dr. Wilfret started his pharmaceutical career in early-stage development at GlaxoSmithKline developing antiviral drugs for HIV, HCV, and respiratory tract infections and later intravenous zanamivir for hospitalized influenza patients.
Dr. Wilfret received his B.S., with high honors, in Biochemistry and Molecular Biology from the University of Florida, where he was elected Phi Beta Kappa, and later received his M.D., also from the University of Florida. Afterwards, he completed his residency in Pediatrics at Wake Forest University Baptist Medical Center and fellowships in Pediatric Infectious Diseases and Pediatric Blood and Marrow Transplantation from Duke University Medical Center. Dr. Wilfret is Board Certified in Pediatrics and Pediatric Infectious Diseases.